TCM
PDSB icon

Tang Capital Management’s PDS Biotechnology PDSB Stock Holding History

Tang Capital Management’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-400,000
Closed -$1.99M – 122
2023
Q4 		$1.99M Hold
400,000
– – 0.18% 91
2023
Q3 		$2.02M Buy
400,000
+300,000
+300% +$1.64M 0.29% 70
2023
Q2 		$503K Buy
+100,000
New +$655K 0.07% 87

Other funds holding PDSB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Tang Capital Management's PDSB Position: Q1 2024 in Review

Tang Capital Management sold out of PDS Biotechnology (PDSB) in Q1 2024, closing a stake of 400,000 shares — an estimated $1.99M sold.

Tang Capital Management first reported a position in PDSB in Q2 2023 and held it in 3 quarters. The position peaked at $2.02M in Q3 2023. 72 funds tracked by Wall St. Rank hold PDSB as of Q1 2024.

  • Tang Capital Management reported no remaining PDS Biotechnology position as of Q1 2024 after selling out during the quarter.
  • Tang Capital Management sold 400,000 PDS Biotechnology shares in Q1 2024, an estimated $1.99M.
  • Tang Capital Management first reported a position in PDS Biotechnology in Q2 2023 and held it in 3 quarters.
  • Tang Capital Management's PDS Biotechnology position peaked at $2.02M in Q3 2023.
  • 72 funds tracked by Wall St. Rank held PDS Biotechnology as of Q1 2024.

Based on Tang Capital Management's 13F filing for Q1 2024, filed 15 May 2024.